-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $18

Benzinga·11/05/2025 19:36:35
Listen to the news
JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $16 to $18.